Thomas Egenod

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

Marie Wislez, Julien Mazières, A. Lavolé et al. · Journal for ImmunoTherapy of Cancer · 2022 · 114 citations · Full text

Medicine, Oncology, Chemotherapy +14

1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)

Marie Wislez, Julien Mazières, A. Lavolé et al. · Annals of Oncology · 2020 · 58 citations

Medicine, Oncology, Thoracic Oncology +10

Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers

Matthieu Dusselier, Élise Deluche, Nellie Delacourt et al. · PLoS ONE · 2019 · 57 citations · Full text

Medicine, Immunology, Oncology +16

OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)

Olivier Molinier, Clarisse Audigier-Valette, J. Cadranel et al. · Journal of Thoracic Oncology · 2017 · 39 citations · Full text

Medicine, Oncology, Pharmacology +9

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study

Fabrice Barlési, A. Dixmier, D. Debieuvre et al. · OncoImmunology · 2020 · 38 citations · Full text

Medicine, Oncology, Pharmacotherapy +16